Depressive symptoms in pulmonary arterial hypertension: Prevalence and association with functional status

Psychosomatics

Volumn 51, Issue 4, 2010, Pages

  McCollister, Deborah H ^a   Beutz, Michelle ^a   Mclaughlin, Vallerie ^a   Rumsfeld, John ^a   Masoudi, Frederick A ^a   Tripputi, Mark ^a   Yaeger, Thomas ^a   Weintraub, Philippe ^a   Badesch, David B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; BIOLOGICAL MARKER;

ARTICLE; CONGENITAL HEART DISEASE; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PHQ 8 SCALE; PREVALENCE; PULMONARY HYPERTENSION; RATING SCALE; SCLERODERMA; SCREENING; SIX MINUTE WALK DISTANCE TEST; SYMPTOM; WALKING; BLOOD; COHORT ANALYSIS; COLORADO; COMORBIDITY; DAILY LIFE ACTIVITY; EXERCISE TEST; HEALTH STATUS; MICHIGAN; PILOT STUDY; PROCEDURES; PSYCHOLOGY; QUESTIONNAIRE; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA;

ACTIVITIES OF DAILY LIVING; BIOMARKERS; COHORT STUDIES; COLORADO; COMORBIDITY; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; EXERCISE TEST; FEMALE; HEALTH STATUS; HUMANS; HYPERTENSION, PULMONARY; MALE; MICHIGAN; PILOT PROJECTS; PREVALENCE; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES;

EID: 77955623203     PISSN: 00333182     EISSN: 15457206     Source Type: Journal    
DOI: 10.1176/appi.psy.51.4.339     Document Type: Article

References (45)

1. Simonneau G, Rubin LJ, Galiè N, et al: Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008; 149:521-530
2. Farber HW, Loscalzo J: Pulmonary arterial hypertension. N Engl J Med 2004; 351:1655-1665
3. McLaughlin VV, McGoon MD: Pulmonary arterial hypertension. Circulation 2006; 114:1417-1431
4. McLaughlin V, Humbert M, Coghlan G, et al: Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology (Oxford) 2009; 48(suppl 3):iii25-iii31
5. Badesch DB, Abman SH, Ahearn GS, et al: Medical Therapy for Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines. Chest 2004; 126(suppl 1):35S-62S
6. Badesch DB, Abman SH, Ahearn GS, et al: Medical Therapy for Pulmonary Arterial Hypertension: Updated ACCP Evidence-Based Clinical Practice Guidelines. Chest 2007; 131:1917-1928 (Pubitemid 46981654)
7. Humbert M, Sitbon O, Simonneau G: Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351:1425-1436
8. Barst RJ, Rubin LJ, Long WA, et al: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334:296-302
9. Badesch DB, Tapson VF, McGoon MD, et al: Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Ann Intern Med 2000; 132:425-434
10. Rubin LJ, Badesch DB, Barst RJ, et al: Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346:896-903 (Pubitemid 34984638)
11. Galiè N, Badesch DB, Oudiz RJ, et al: Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005; 46: 529-535 (Pubitemid 41040298)
12. Galiè N, Olschewski H, Oudiz RJ, et al: Ambrisentan for the treatment of pulmonary arterial hypertension: results of the Ambrisentan in Pulmonary Arterial Hypertension Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2. Circulation 2008; 117:3010-309
13. Galiè N, Ghofrani HA, Torbicki A, et al: Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353:2148-2157 (Pubitemid 41653106)
14. Galiè N, Brundage BH, Ghofrani HA, et al: Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119:2894-2903
15. Simonneau G, Barst RJ, Galiè N, et al: Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 800-804 (Pubitemid 34229650)
16. Olschewski H, Simonneau G, Galiè N, et al: Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347:322-329 (Pubitemid 34815354)
17. Barst RJ, Gibbs JS, Ghofrani HA, et al: Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54(suppl 1):S78-S84
18. McLaughlin VV, Archer SL, Badesch DB, et al: ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53:1573-1619
19. Badesch DB, Raskob GE, Elliott CG, et al: Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010; 137:376-387
20. Kroenke K, Strine TW, Spitzer RL, et al: The PHQ-8 as a measure of current depression in the general population. J Affect Disord 2009; 114:163-173
21. Kaplan H, Sadock BJ, Sadock VA: Concise Textbook of Clinical Psychiatry. Philadelphia, PA, Lippincott, Williams & Wilkins, 1996
22. Kessler RC, Chiu WT, Demler O, et al: Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey replication. Arch Gen Psychiatry 2005; 62: 617-627 (Pubitemid 40973437)
23. Rumsfeld JS, Havranek E, Masoudi FA, et al: Depressive symptoms are the strongest predictors of short-term declines in health status in patients with heart failure. J Am Coll Cardiol 2003; 42:1811-187
24. Löwe B, Gräfe K, Ufer C, et al: Anxiety and depression in patients with pulmonary hypertension. Psychosom Med 2004; 66:831-836 (Pubitemid 39552865)
25. Miller GE, Stetler CA, Carney RM, et al: Clinical depression and inflammatory risk markers for coronary heart disease. Am J Cardiol 2002; 90:1279-1283 (Pubitemid 35449470)
26. Kéreveur A, Callebert J, Humbert M, et al: High plasma serotonin levels in primary pulmonary hypertension: effect of longterm epoprostenol (prostacyclin) therapy. Arterioscler Thromb Vasc Biol 2000; 20:2233-2239
27. Hervé P, Launay JM, Scrobohaci ML, et al: Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995; 99:249-254
28. MacLean MR, Dempsie Y: Serotonin and pulmonary hypertension: from bench to bedside? Curr Opin Pharmacol 2009; 9:281-286
29. Nagaya N, Nishikimi T, Uematsu M, et al: Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000; 102:865-870
30. Guyatt GH, Sullivan MJ, Thompson PJ, et al: The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 1985; 132:919-923
31. Miyamoto S, Nagaya N, Satoh T, et al: Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000; 161:487-492 (Pubitemid 30129457)
32. Spitzer RL, Kroenke K, Williams JB: Validation and utility of a self-report version of PRIME-MD: the PHQ Primary Care Study: primary care evaluation of mental disorders, Patient Health Questionnaire. JAMA 1999; 282:1737-1744
33. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Washington, DC, American Psychiatric Association, 1994
34. Ruo B, Rumsfeld JS, Hlatky MA, et al: Depressive symptoms and health-related quality of life: the Heart and Soul Study. JAMA 2003; 290:215-221 (Pubitemid 37430060)
35. Kroenke K, Spitzer RL, Williams JB: The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16:606-613 (Pubitemid 32823891)
36. Judd LL, Schettler PJ, Akiskal HS: The prevalence, clinical relevance, and public health significance of subthreshold depressions. Psychiatr Clin North Am 2002; 25:685-698 (Pubitemid 35351201)
37. Rumsfeld JS, Magid DJ, Plomondon ME, et al: History of depression, angina, and quality of life after acute coronary syndromes. Am Heart J 2003; 145:493-499 (Pubitemid 36390496)
38. Ziegelstein RC: Depression in patients recovering from a myocardial infarction. JAMA 2001; 286:1621-1627 (Pubitemid 33010287)
39. Kendler KS, Karkowski LM, Prescott CA: Causal relationship between stressful life events and the onset of major depression. Am J Psychiatry 1999; 156:837-841 (Pubitemid 29260336)
40. Janson C, Björnsson E, Hetta J, et al: Anxiety and depression in relation to respiratory symptoms and asthma. Am J Respir Crit Care Med 1994; 149:930-934 (Pubitemid 24108484)
41. Al-shair, K, Dockry R, Mallia-Milanes B, et al: Depression and its relationship with poor exercise capacity, BODE index, and muscle-wasting in COPD. Respir Med 2009; 103:1572-1579
42. Looper KJ, Pierre A, Dunkley DM, et al: Depressive symptoms in relation to physical functioning in pulmonary hypertension. J Psychosom Res 2009; 66:221-225
43. McLaughlin VV, Badesch DB, Delcroix M, et al: End-points and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54(suppl 1):S97-S107
44. Fijalkowska A, Kurzyna M, Torbicki A, et al: Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 2006; 129:1313-1321
45. Ridker PM, Hennekens CH, Buring JE, et al: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836-843 (Pubitemid 30165206)